These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38059346)

  • 21. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receipt of Medication and Behavioral Therapy Among a National Sample of School-Age Children Diagnosed With Attention-Deficit/Hyperactivity Disorder.
    Walls M; Allen CG; Cabral H; Kazis LE; Bair-Merritt M
    Acad Pediatr; 2018 Apr; 18(3):256-265. PubMed ID: 29061327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term?
    Cortese S
    J Am Acad Child Adolesc Psychiatry; 2019 Oct; 58(10):936. PubMed ID: 31254608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADHD: new pharmacological treatments on the horizon.
    López FA
    J Dev Behav Pediatr; 2006 Oct; 27(5):410-6. PubMed ID: 17041279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 28. New options in the pharmacological management of attention-deficit/hyperactivity disorder.
    Olfson M
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder.
    Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
    Pediatrics; 2002 May; 109(5):733-9. PubMed ID: 11986429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents.
    Childress AC; Berry SA
    Drugs; 2012 Feb; 72(3):309-25. PubMed ID: 22316347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attention-deficit/hyperactivity disorder and substance abuse.
    Harstad E; Levy S;
    Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence-based pharmacological treatment options for ADHD in children and adolescents.
    Mechler K; Banaschewski T; Hohmann S; Häge A
    Pharmacol Ther; 2022 Feb; 230():107940. PubMed ID: 34174276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013-2020).
    Bruno C; Havard A; Gillies MB; Coghill D; Brett J; Guastella AJ; Pearson SA; Zoega H
    Aust N Z J Psychiatry; 2023 May; 57(5):675-685. PubMed ID: 35999695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
    Childress A; Burton S
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.